Black Diamond Therapeutics is a clinical-stage oncology company developing targeted therapies for genetically defined cancers. Its core concept is "MasterKey" therapies — drug molecules designed to inhibit entire families of oncogenic mutations by exploiting shared structural features, rather than targeting a single mutation. The lead asset is silevertinib, a brain-penetrant, irreversible oral EGFR inhibitor being developed for two indications: EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM). In NSCLC, silevertinib targets non-classical EGFR mutations underserved by the standard-of-care osimertinib, as well as the C797S resistance mutation that emerges after third-generation EGFR inhibitors — an indication for which silevertinib has received FDA Fast Track Designation. Phase 2 data in frontline non-classical NSCLC patients showed a 60% objective response rate. In GBM, a randomized Phase 2 trial is planned for Q2 2026. Black Diamond has two other pipeline assets: BDTX-4933, a RAF inhibitor outlicensed to Servier for $70M upfront plus milestones, and BDTX-4876, a preclinical FGFR2/3 inhibitor for which Black Diamond is seeking a partner. Black Diamond is pre-revenue and funds operations through equity raises and licensing deals. The company is exploring partnerships for silevertinib's pivotal development; absent a partner, Black Diamond would sell the drug directly to oncologists and hospitals if approved.